Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adequacy, Advisory, Amgen, Anderson, Area, attached, Biogen, biological, BioMedix, blocker, broader, BVF, Center, chairman, characterization, circumvention, Cody, conclusion, confidence, Council, CTEP, David, deliverable, description, discretionary, DuPont, effectuate, Enterprise, Essa, expressly, feature, Fiber, Fischer, flow, Frazier, Geneva, Head, Helix, hereto, Iceland, Idec, immunotherapy, indirect, insignificant, investor, Jennerex, Kirske, Laurent, Liechtenstein, liver, Mad, malignancy, Medal, memorandum, mentioned, modification, NEA, Nodality, Ocera, oncolytic, par, pari, Parkinson, Parliament, passu, proportion, proportional, Puget, recover, reliable, remediate, Roche, role, salary, Science, Sillajen, Sound, standalone, Switzerland, temporary, unamortized, undergraduate, underwriting, underwritten, virology, workforce
Removed:
accrual, decided, defend, interpretive, trend, unspecified, vigorously
Filing tables
Filing exhibits
Related press release
CTIC similar filings
Filing view
External links
Exhibit 15
August 3, 2017
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We are aware that our report (which includes an explanatory paragraph as to the Company’s ability to continue as a going concern) dated August 3, 2017 on our review of interim financial information of CTI BioPharma Corp. for the three- and six-month periods ended June 30, 2017 and 2016, and included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2017, is incorporated by reference in the Registration Statements of CTI BioPharma Corp. on Forms S-3 (Nos. 333-108926, 333-134126, 333-149980, 333-149981, 333-152171, 333-157376, 333-160969, 333-161442, 333-163479, 333-177506, 333-182330, 333-183037, 333-192748, 333-192749, 333-200452 and 333-200453) and Forms S-8 (Nos. 333-146624, 333- 152168, 333-158260, 333-162955, 333-170044, 333-178158, 333-184004, 333-189611, 333-196510, 333-207176, 333-207177, 333-211006, 333-218946 and 333-218947).
Yours very truly,
/s/Marcum LLP
Marcum LLP
San Francisco, California
August 3, 2017